Literature DB >> 9740774

Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties.

F Habersetzer1, A Fournillier, J Dubuisson, D Rosa, S Abrignani, C Wychowski, I Nakano, C Trépo, C Desgranges, G Inchauspé.   

Abstract

Both linear and conformational determinants of hepatitis C virus (HCV) are believed to be involved in viral neutralization. After immortalization of B cells from HCV chronically infected patients with Epstein-Barr virus, we obtained two polyclonal lymphoblastoid cell lines (LCL) secreting human monoclonal antibodies (HMabs). One clone was derived from a patient infected with a genotype 4 isolate while the second was isolated from a genotype 1b-infected patient. Immunoprecipitation studies, Western blot, and immunofluorescence analysis, peptide scanning, and ELISA studies indicated that the HMabs (1) recognized conformation-dependent determinant(s), (2) were capable of recognizing genotype 1a and 1b derived antigens, and (3) were able to precipitate noncovalently associated E1E2 complexes believed to exist on the surface of virion particles. The HMab derived from the genotype 4-infected patient was in addition shown to neutralize the in vitro binding of recombinant E2 protein onto susceptible cells suggesting a potential for in vivo neutralization. These data indicate that anti-E2 antibodies directed at conserved conformational-dependent determinant(s) exist in chronic HCV infection. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740774     DOI: 10.1006/viro.1998.9202

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

2.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

3.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 6.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

7.  In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Authors:  Meital Gal-Tanamy; Zhen-Yong Keck; MinKyung Yi; Jane A McKeating; Arvind H Patel; Steven K H Foung; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

8.  A novel small molecule inhibitor of hepatitis C virus entry.

Authors:  Carl J Baldick; Michael J Wichroski; Annapurna Pendri; Ann W Walsh; Jie Fang; Charles E Mazzucco; Kevin A Pokornowski; Ronald E Rose; Betsy J Eggers; Mayla Hsu; Weixu Zhai; Guangzhi Zhai; Samuel W Gerritz; Michael A Poss; Nicholas A Meanwell; Mark I Cockett; Daniel J Tenney
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

9.  Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein.

Authors:  Roxana E Iacob; Zhenyong Keck; Oakley Olson; Steven K H Foung; Kenneth B Tomer
Journal:  Biochim Biophys Acta       Date:  2008-01-11

10.  Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Authors:  Ania M Owsianka; Alexander W Tarr; Zhen-Yong Keck; Ta-Kai Li; Jeroen Witteveldt; Richard Adair; Steven K H Foung; Jonathan K Ball; Arvind H Patel
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.